Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates-Reference-Cited by-同舟云学术

Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

Published:2014-04-15 Issue:3 Volume:20 Page:322-325
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Giangrande P.¹²,Seitz R.³,Behr-Gross M. E.⁴,Berger K.⁵,Hilger A.³,Klein H.⁶,Schramm W.⁷,Mannucci P. M.⁸

Affiliation:

1. Oxford Haemophilia and Thrombosis Centre; Oxford UK

2. European Haemophilia Consortium; Brussels Belgium

3. Paul-Ehrlich-Institut; Langen Germany

4. European Directorate for the Quality of Medicines & HealthCare (EDQM); Strasbourg France

5. University Hospital of Munich; Munich Germany

6. National Institutes of Health; Bethesda MD USA

7. Rudolf-Marx-Stiftung; Munich Germany

8. Fondazione IRCCS Ca’ Granda Ospedale Maggiore; Milan Italy

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12440/fullpdf

Reference9 articles.

1. Haemophilia care in Europe - a survey of 35 countries;O'Mahony;Haemophilia,2013

2. European Symposium: Optimal use of clotting factors and immunoglobulins Strasbourg 2013

3. Back to the future: a recent history of haemophilia treatment;Mannucci;Haemophilia,2008

4. Molecular approaches for improved clotting factors for hemophilia;Kaufman;Blood,2013

5. Communication from the Commission to the Council, the European Parliament and the Economic and Social Committee on blood Self-Sufficiency in the European Community 1993 13

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma‐derived human factor X concentrate for the treatment of patients with hereditary factor X deficiency;Haemophilia;2023-10-30

2. Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A;Research and Practice in Thrombosis and Haemostasis;2023-01

3. A review of the pharmacokinetics, efficacy and safety of high‐purity factor X for the prophylactic treatment of hereditary factor X deficiency;Haemophilia;2022-05-02

4. The Cost of Von Willebrand Disease in Europe: The CVESS Study;Clinical and Applied Thrombosis/Hemostasis;2022-01

5. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency;Blood Reviews;2021-11